Gilead Sciences (GILD) said Monday its two applications for lenacapavir as a pre-exposure prophylaxis to prevent HIV have been validated for parallel accelerated review by the European Medicines Agency.
The company said one application is for a marketing authorization and another is an EU-Medicines for all, or EU-M4all, application to facilitate expedited review processes for the injectable HIV-1 capsid inhibitor in other countries outside the EU.
Both applications are supported by phase 3 data that showed twice-yearly lenacapavir achieved risk reduction in HIV infections of 96% to 100%, the company added.
Gilead Sciences said the EMA validation followed the acceptance by the US Food and Drug Administration of its new drug applications for lenacapavir.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.